Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:21 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response
NCT05593770 · NEAT ID Foundation · PHASE2/PHASE3 · terminated · last registry update 2025-05-02 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Following a meeting of the DSMB on 20th September 2023, the recommendation was made to the sponsor on 26th September 2023 that the Fostamatinib arm of the trial ceases enrolment and study medication is discontinued immediately.” | – | Registry record, NEAT ID Foundation |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SYK within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-12-05Results posted on the registry: National Heart, Lung, and Blood Institute (NHLBI), fostamatinib (NCT05502783)
- 2025-12-05Also stopped (terminated): National Heart, Lung, and Blood Institute (NHLBI), fostamatinib (NCT05502783)
- 2025-11-10Also stopped (withdrawn): National Heart, Lung, and Blood Institute (NHLBI), fostamatinib (NCT05509582)
- 2025-09-16Also stopped (withdrawn): Hutchmed, HMPL-523 (NCT06291415)
- 2025-08-11Results posted on the registry: Kissei Pharmaceutical Co., Ltd., R788 + Placebo (NCT04132050)
- 2025-06-17Results posted on the registry: Gilead Sciences, Tirabrutinib + Idelalisib (NCT02457598)
- 2025-06-17Also stopped (terminated): Gilead Sciences, Tirabrutinib + Idelalisib (NCT02457598)
- 2025-03-13Also stopped (withdrawn): National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Gusacitinib (NCT06238531)
- 2025-01-22Results posted on the registry: Sean Collins, TXA127 + TRV027 (NCT04924660)
- 2024-09-19Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Fostamatinib 100 mg bid and Paclitaxel + Fostamatinib 150 mg bid and Paclitaxel (NCT03246074)
- 2024-08-07Results posted on the registry: Kronos Bio, Lanraplenib + Gilteritinib (NCT05028751)
- 2024-08-07Also stopped (terminated): Kronos Bio, Lanraplenib + Gilteritinib (NCT05028751)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision